Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alexandria Real Estate Equities Inc (ARE) vs CVS Health Corp (CVS) Price & Performance

Alexandria Real Estate Equities IncTrade
CVS Health CorpTrade

Price performance (Past 24H)

Key statistics

Alexandria Real Estate Equities Inc vs CVS Health Corp — how do they compare? Alexandria Real Estate Equities Inc trades at $47.9 (market cap $8.34B), while CVS Health Corp trades at $104.16 (market cap $132.89B). The key difference: CVS Health Corp is far larger — about 15.9× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals.

ARECVS
Market Cap
$8.34B$132.89B
Sector
Real EstateHealth
52-Week High
$87.45$104.81
52-Week Low
$40.41$58.75
Enterprise Value
$20.80B$199.43B
Dividend Yield
6.02%2.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities (ARE) trades at $47.88, down 1.3% on the day, with a bearish technical signal and mixed fundamentals. The stock shows a high P/E of 102.99 and negative net income margin of -37.09%, though it maintains a strong gross margin of 67.76% and positive operating cash flow. Recent news highlights corporate responsibility initiatives and a declared dividend of $0.72 per share for Q2 2026.

The outlook is cautious due to profitability challenges and elevated debt, but analyst consensus suggests moderate upside to a $51.00 price target. Key risks include sustained negative earnings and interest rate sensitivity, while institutional sentiment leans neutral with 58.33% hold ratings.

CVS Health Corp

CVS Health trades at $104.15, up 1.3% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q1 2026 EPS of $2.57 exceeding expectations of $2.18. Revenue growth remains robust at $402.07B for 2025, though net margins have compressed to 0.72%. Recent dividend declarations and positive media coverage highlight the company's stable cash flow generation and market positioning.

CVS presents a compelling investment case with 84.6% analyst buy ratings and a $107.29 consensus target offering 3% upside. However, investors face risks from declining profitability margins, elevated debt levels at 25.48% debt-to-asset ratio, and competitive pressures in the healthcare sector. The stock's current valuation at 45.68 P/E requires careful monitoring of margin improvement initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Read more on ARE

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS